BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26951660)

  • 1. Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.
    Houlleberghs H; Dekker M; Lantermans H; Kleinendorst R; Dubbink HJ; Hofstra RM; Verhoef S; Te Riele H
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4128-33. PubMed ID: 26951660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
    Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
    J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome.
    Bouvet D; Bodo S; Munier A; Guillerm E; Bertrand R; Colas C; Duval A; Coulet F; Muleris M
    Gastroenterology; 2019 Aug; 157(2):421-431. PubMed ID: 30998989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncation of the MSH2 C-terminal 60 amino acids disrupts effective DNA mismatch repair and is causative for Lynch syndrome.
    Wielders E; Delzenne-Goette E; Dekker R; van der Valk M; Te Riele H
    Fam Cancer; 2017 Apr; 16(2):221-229. PubMed ID: 27873144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity.
    Houlleberghs H; Goverde A; Lusseveld J; Dekker M; Bruno MJ; Menko FH; Mensenkamp AR; Spaander MCW; Wagner A; Hofstra RMW; Te Riele H
    PLoS Genet; 2017 May; 13(5):e1006765. PubMed ID: 28531214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
    Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
    Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.
    Rath A; Mishra A; Ferreira VD; Hu C; Omerza G; Kelly K; Hesse A; Reddi HV; Grady JP; Heinen CD
    Hum Mutat; 2019 Nov; 40(11):2044-2056. PubMed ID: 31237724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic screens to identify pathogenic gene variants in the common cancer predisposition Lynch syndrome.
    Drost M; Lützen A; van Hees S; Ferreira D; Calléja F; Zonneveld JB; Nielsen FC; Rasmussen LJ; de Wind N
    Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9403-8. PubMed ID: 23690608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.
    Drost M; Zonneveld JB; van Hees S; Rasmussen LJ; Hofstra RM; de Wind N
    Hum Mutat; 2012 Mar; 33(3):488-94. PubMed ID: 22102614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-step site-directed mutagenesis screen identifies pathogenic
    Houlleberghs H; Dekker M; Lusseveld J; Pieters W; van Ravesteyn T; Verhoef S; Hofstra RMW; Te Riele H
    J Med Genet; 2020 May; 57(5):308-315. PubMed ID: 31784484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance-functional analysis reveals the pathogenic one.
    Kantelinen J; Hansen TV; Kansikas M; Krogh LN; Korhonen MK; Ollila S; Nyström M; Gerdes AM; Kariola R
    Fam Cancer; 2011 Sep; 10(3):515-20. PubMed ID: 21431882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
    Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
    Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs found in cancer patients.
    Kantelinen J; Kansikas M; Candelin S; Hampel H; Smith B; Holm L; Kariola R; Nyström M
    Hum Mutat; 2012 Aug; 33(8):1294-301. PubMed ID: 22581703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR).
    Chao EC; Velasquez JL; Witherspoon MS; Rozek LS; Peel D; Ng P; Gruber SB; Watson P; Rennert G; Anton-Culver H; Lynch H; Lipkin SM
    Hum Mutat; 2008 Jun; 29(6):852-60. PubMed ID: 18383312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of HNPCC-related missense mutations in MSH2.
    Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
    Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive functional assay-based classification of PMS2 variants in Lynch syndrome.
    Rayner E; Tiersma Y; Fortuno C; van Hees-Stuivenberg S; Drost M; Thompson B; Spurdle AB; de Wind N
    Hum Mutat; 2022 Sep; 43(9):1249-1258. PubMed ID: 35451539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of pathogenicity in human MSH2 missense mutants.
    Ollila S; Dermadi Bebek D; Jiricny J; Nyström M
    Hum Mutat; 2008 Nov; 29(11):1355-63. PubMed ID: 18951462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verification of the three-step model in assessing the pathogenicity of mismatch repair gene variants.
    Kansikas M; Kariola R; Nyström M
    Hum Mutat; 2011 Jan; 32(1):107-15. PubMed ID: 21120944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.